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A B S T R A C T
First described as essential to the phagocytic activity of leukocytes, Nox2-derived ROS have emerged as med-
iators of a range of cellular and tissue responses across species from salubrious to deleterious consequences.
Knowledge of their role in inflammation is limited, however. We postulated that TNFα-induced endothelial
reactive oxygen species (ROS) generation and pro-inflammatory signaling would be ameliorated by targeting
Nox2. Herein, we in silico-modelled two first-in-class Nox2 inhibitors developed in our laboratory, explored their
cellular mechanism of action and tested their efficacy in in vitro and mouse in vivo models of inflammation. Our
data show that these inhibitors (CPP11G and CPP11H) disrupted canonical Nox2 organizing factor, p47phox,
translocation to Nox2 in the plasma membrane; and abolished ROS production, markedly attenuated stress-
responsive MAPK signaling and downstream AP-1 and NFκB nuclear translocation in human cells. Consequently,
cell adhesion molecule expression and monocyte adherence were significantly inhibited by both inhibitors. In
vivo, TNFα-induced ROS and inflammation were ameliorated by targeted Nox2 inhibition, which, in turn, im-
proved hind-limb blood flow. These studies identify a proximal role for Nox2 in propagated inflammatory sig-
naling and support therapeutic value of Nox2 inhibitors in inflammatory disease.
1. Introduction
NADPH oxidases (Noxs) comprise a family of seven isozymes whose
only known function is the generation of reactive oxygen species (ROS)
[1–7]. Besides their evermore-accepted role as signaling molecules,
under pathophysiological conditions, excessive ROS production con-
tributes to cell and tissue damage by oxidative stress and, as a con-
sequence, to the development of myriad diseases. Noxs play a key role
in stress and attendant disease, including varied cardiovascular mala-
dies [7–11], cancer [12,13], and neurodegenerative disorders [14,15].
These encompass many of the major leading causes of death in the
United States [16] and around the world. As the demand for selective
Nox inhibitors for pharmacological and therapeutic purposes has be-
come increasingly clear, drug development both from pharmaceutical
industry and academia has intensified in recent years. Still, the need for
well-characterized, isoform-specific inhibitors has not been met
[7,17,18].
Our laboratory identified two bridged tetrahydroisoquinolines as
small molecule inhibitors with high selectivity for the Nox2 isozyme
[19]. In that study, the inhibitory potential of these molecules was
preliminarily characterized using COS- and HEK- heterologous systems
that expressed components of replete Nox isozyme systems and a non-
Nox ROS generator. While these inhibitors demonstrated high Nox2
selectivity in a system of Nox subunit overexpression, their inhibitory
profile in vivo and in parenchymal primary cells in vitro were neither
interrogated nor their mechanism of action in cellular processes ex-
plored.
In this study, we beta-tested novel Nox2 inhibitors CPP11G and
CPP11H [previously referred to as compounds 11g and 11h [19]] in in
vitro and in vivo human and mouse inflammatory models, respectively,
and examined the impact of Nox2 on a wide array of oxidant-sensitive
signaling pathways leading to adhesion molecule expression, monocyte
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adhesion, vascular dysfunction and disrupted hind-limb blood flow.
Herein, we model, in silico, the interaction of these compounds with 2
crucial binding domains within the canonical Nox2 (comprised of Nox2,
p22phox, p47phox, p67phox, and Rac1/2) and report for the first time that
they effectively block Nox2 activity by interfering with p47phox cytosol
to membrane translocation and its interaction with cytochrome b558
heavy chain (CYBB). Furthermore, our findings reveal that TNFα-sti-
mulated Nox2-derived ROS, MAPK activation, AP-1 and NFκB phos-
phorylation and nuclear translocation, adhesion molecule expression,
endothelial dysfunction and impaired peripheral blood flow are all
ameliorated by the Nox2 inhibitors. In aggregate, the findings hold
meaningful promise for these agents and their derivatives as viable
therapeutics in the treatment of myriad Nox2-actuated disorders.
2. Results
2.1. In silico analysis of Nox2 inhibitors modeling disruption of critical
Nox2 oxidase subunit p47phox:p22phox interactions, and in vitro proof of
blockade of p47phox binding to cytochrome b558 heavy chain (Nox2)
In silico interaction analysis of CPP11G and CPP11H with atomic
structures of key components of the Nox2 oxidase was exploited
(Fig. 1A). Modeling predicted that they interfere with a well-defined
p47phox-SH3 “super groove” domain key interaction with a proline-rich
(PRR) domain on the C-terminus of p22phox that is established as pivotal
for the docking of p47phox to the membrane-spanning cytochrome b558
light chain p22phox [6,20–23]. This informed the hypothesis that these
compounds would interfere with cytosolic p47phox interactions with
membrane-integrated cytochrome components (either p22phox or Nox2)
upon Nox activation. To interrogate this potential interference, COS-
phox cells overexpressing the Nox2 isozyme subunits were classically
stimulated with a phorbol ester. As shown in Fig. 1B, levels of p47phox at
the plasma membrane were significantly elevated by phorbol 12-myr-
istate 13-acetate (PMA, 5 μmol/l), a known protein kinase C activator
Fig. 1. Nox2 inhibitors disrupt p47phox membrane translocation and interaction with the Nox2-p22phox complex. (A) In silico 3D-modeling based on PDB 1OV3
showing (i) both Nox2 inhibitors CPP11G & H interfering with p22phox C-terminal PRR domain interaction with the p47phox Src homology 3 (SH3) domain (super
groove) (overlay); (ii) the p22phox C-terminus alone interacting with the p47phox SH3 super groove, (iii, iv) Selective Nox2 inhibitors binding individually to the
p47phox super groove. (B) Western blotting of membrane fraction showing the effects of CPP11G (20 μmol/l) and CPP11H (20 μmol/l) on PMA (5 μmol/l)-induced
p47phox membrane translocation in COS-phox cells overexpressing Nox2 subunits. The band density of p47phox protein in the membrane fraction was normalized to
the density of Nox2 band detected in the same sample, n = 5 (*p < 0.05 vs. control, Ctrl, ##p < 0.01 vs. PMA.) (C) Western blotting showing the effects of
CPP11G (20 μmol/l) and CPP11H (20 μmol/l) on PMA (5 μmol/l)-stimulated interaction between p47phox and Nox2 in COS-phox cells overexpressing Nox2 subunits.
p47phox was immunoprecipitated (IP) from COS-phox homogenates and detected by Western blot for the presence of Nox2. The densities of Nox2 protein binds were
normalized to the levels of p47phox detected in the same samples, n = 6 (*p < 0.05 vs. Ctrl, ###p < 0.001 vs. PMA).
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which causes phosphorylation of p47phox and triggers its membrane
translocation. This response was inhibited in the presence of CPP11G
and CPP11H (Fig. 1B). To further investigate their effects on the in-
teraction between p47phox and Nox2, co-immunoprecipitation was ap-
plied on a preparation of COS-phox cells, where PMA (5 μmol/l) sti-
mulation increased Nox2 to p47phox binding (Fig. 1C). Consistent with
the results on p47phox membrane translocation, both agents diminished
PMA-induced interaction between Nox2 and p47phox. In summary,
CPP11G and CPP11H suppressed p47phox cytosol-to-membrane trans-
location, thus blocking the Nox2 isozyme complex formation and by
extension ROS-producing activity.
2.2. CPP11G and CPP11H inhibit Nox2-derived ROS production, MAPK/
SAPK signaling and AP-1 activation in response to TNFα
To evaluate the effectiveness of these Nox2 inhibitors under more
physiological conditions, primary human aortic endothelial cells
(HAECs) were employed to establish an acute inflammatory model of
TNFα stimulation (10 ng/ml) in which the agents were optimally beta-
tested. As expected, HAECs challenged with TNFα yielded increased
amounts of O2•‒, which was measured using the fluorescent hydro-
propidine (HPr+), a cell-impermeant probe for detecting extracellular
O2•‒. Importantly, both CPP11G and CPP11H (10 μmol/l) obliterated
this response (Fig. 2A). Next, as O2•‒ is rapidly dismuted to H2O2, levels
of H2O2 stimulated by TNFα and the effects of the Nox2 inhibitors were
assessed using a recently optimized coumarin-7-boronic acid (CBA) as
well as the Amplex Red assay on whole cells and cell homogenates,
respectively (Figs. 2B and C). Consistent with the O2•‒ results, TNFα-
stimulated elevation in H2O2 was effectively blocked by both com-
pounds (each at 10 μmol/l). Moreover, excessive generation of O2•‒
gives rise to peroxynitrite (ONOO−), a highly reactive and often de-
structive ROS that oxidizes lipoproteins and nitrosates tyrosine residues
in many proteins, forming 3-nitrotyrosine (3-NT) [24], a well-estab-
lished “footprint” biomarker of oxidative damage. Indeed, HAECs
treated with TNFα (10 ng/ml) for 24 h exhibited increased (∼2 fold vs.
control, Ctrl) 3-NT formation as evidenced by stronger immuno-
fluorescent staining. In comparison, HAECs that were pretreated with
CPP11G (10 μmol/l) or CPP11H (10 μmol/l) revealed significantly
lower levels of 3-NT than cells with TNFα alone (Fig. 2D), indicating by
a fourth independent method that these inhibitors are capable of lim-
iting Nox2-derived ROS in HAECs.
Next, we examined their effects on TNFα-induced Nox2-mediated
mitogen-activated protein kinase (MAPK) signaling. TNFα (10 ng/ml)
triggered a rapid and transient phosphorylation of p38 MAPK, which
peaked at 10min (6.9 ± 0.6 fold vs. Ctrl) and dropped below baseline
by 30min (Supplementary Fig. 1A). Similarly, SAPK/JNK phosphor-
ylation in response to TNFα (10 ng/ml) was also transiently time-de-
pendent, which achieved a maximum but transitory stimulation at
20min with TNFα stimulation (10.3 ± 0.6 fold vs. Ctrl)
(Supplementary Fig. 1B). Unexpectedly, no stimulations in ERK1/2
(p44/42) MAPK phosphorylation were observed within the first hour or
even after prolonged TNFα (10 ng/ml) treatment (up to 24 h)
(Supplementary Figs. 1C and D), suggesting that TNFα and subsequent
Nox-derived ROS differentially regulate downstream MAPK signaling.
Fig. 2. Nox2 inhibitors attenuate TNFα-induced reactive oxygen species (ROS) production in human aortic endothelial cells (HAECs). (A) Effects of CPP11G
(10 μmol/l) and CPP11H (10 μmol/l) on TNFα (10 ng/ml)-stimulated extracellular superoxide (O2· ) measured by hydropropidine (HPr+) Assay, n = 4. (**p < 0.01
vs. Ctrl, ####p < 0.0001 vs. TNFα). (B) Effects of CPP11G (10 μmol/l) and CPP11H (10 μmol/l) on TNFα (10 ng/ml)-stimulated hydrogen peroxide (H2O2)
production measured by coumarin-7-boronic acid (CBA) Assay, n = 6. (*p < 0.05 vs. Ctrl, ##p < 0.01 vs. TNFα, ####p < 0.0001 vs. TNFα). (C) Effects of
CPP11G (10 μmol/l) and CPP11H (10 μmol/l) on TNFα (10 ng/ml, 10 min)-stimulated H2O2 production examined by Amplex Red Assay, n = 6–7. (*p < 0.05 vs.
Ctrl, ##p < 0.01 vs. TNFα, ###p < 0.001 vs. TNFα). (D) Immunofluorescence microscopy (20×magnification) detection of 3-nitrotyrosine (red) formation upon
24h TNFα (10 ng/ml) stimulation in the presence or absence of CPP11G or CPP11H (10 μmol/l). Nuclei were labelled with DAPI (blue). Fluorescence intensity was
quantified from 3 images/group, n = 3 independent experiments. (****p < 0.0001 vs. Ctrl, ##p < 0.01 vs. TNFα, ####p < 0.0001 vs. TNFα).
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As TNFα-induced intracellular events appeared rapid and transient,
Nox2 inhibitor effects were evaluated at the time of peak activation.
Phosphorylation of p38 by TNFα (10 ng/ml, 10min) was markedly
suppressed by CPP11G and CPP11H by≥50% in a concentration-de-
pendent manner (Fig. 3A). Consistently, activation of SAPK/JNK was
also robustly and concentration-dependently inhibited by CPP11G and
CPP11H (Fig. 3B).
Activated MAPK, particularly SAPK/JNK, phosphorylates the
transactivation domain of c-Jun, a key component of the transcription
factor AP-1, thereby facilitating AP-1 to initiate inflammatory gene
expression [25,26]. Thus, we next investigated the effects of our small
molecule Nox2 inhibitors on c-Jun phosphorylation and nuclear
translocation. With 1 h of TNFα (10 ng/ml) challenge, the ratio of ac-
tive (phosphorylated) c-Jun to total c-Jun in whole cell lysates was
enhanced (2.7 ± 0.2 fold vs. Ctrl). Both CPP11G and CPP11H sig-
nificantly inhibited c-Jun phosphorylation concentration-dependently
(Fig. 3C). Moreover, we were able to show that c-Jun translocated to
the nucleus, where it positively regulates genes involved in endothelial
activation [25,26]. Consistently, we found that TNFα (10 ng/ml, 1 h)
substantially elevated the levels of phospho-c-Jun in the nuclear frac-
tion of endothelial cells (~5-fold) wherein CPP11H exhibited a notably
higher efficacy in diminishing c-Jun nuclear translocation by
60.7 ± 8.0% (p-cJun/Histone); CPP11G displayed a tendency toward
an inhibition (not significant; Fig. 3D). Collectively, these results
Fig. 3. Nox2 inhibitors attenuate TNFα-induced mitogen-activated protein kinase (MAPK) activation in HAECs. (A) Representative Western blots (left) and cu-
mulative data (right) showing concentration dependent inhibition by CPP11G and CPP11H of TNFα (10 ng/ml, 10 min)-stimulated p38 MAPK activation. The
densities of phospho-p38 were normalized to the levels of total p38 detected in the same samples, n = 6–8. (****p < 0.0001 vs. unstimulated, #p < 0.05 vs. TNFα,
##p < 0.01 vs. TNFα, ####p < 0.0001 vs. TNFα). (B) Representative Western blots (left) and cumulative data (right) showing concentration dependent
inhibition by CPP11G and CPP11H of TNFα (10 ng/ml, 20 min)-stimulated JNK phosphorylation. The densities of phospho-JNK were normalized to the levels of total
JNK detected in the same samples, n = 7. (****p < 0.0001 vs. unstimulated, #p < 0.05 vs. TNFα, ##p < 0.01 vs. TNFα). (C) Representative Western blots (left)
and cumulative data (right) showing concentration dependent attenuation by CPP11G and CPP11H of TNFα (10 ng/ml, 1h)-stimulated cJun phosphorylation. The
densities of phospho-cJun were normalized to the levels of total cJun detected in the same samples, n = 6. (****p < 0.0001 vs. unstimulated, #p < 0.05 vs. TNFα,
####p < 0.0001 vs. TNFα). (D) Representative Western blots (left) and cumulative data (right) showing the effects of CPP11G (10 μmol/l) and CPP11H (10 μmol/
l) on TNFα (10 ng/mL, 1h)-modified phospho-cJun levels on the nuclear fraction. The densities of phospho-cJun were normalized to the levels of histone detected in
the same samples, n = 3. (***p < 0.001 vs. control, ###p < 0.001 vs. TNFα).
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indicate that both CPP11G and CPP11H are broadly effective in sup-
pressing TNFα-induced Nox2-mediated MAPK/SAPK and AP-1 sig-
naling.
2.3. Nox2 inhibitors suppress IKK-NFκB pathway induced by TNFα
In addition to the MAPK and AP-1 signaling cascades, TNFα is im-
plicated in Nox2-dependent NFĸB signaling to endothelial inflamma-
tion [27,28]. Hence, we characterized the effects of CPP11G and
CPP11H on the NFκB signaling cascade. Mirroring the mode of MAPK
activation, IκB kinases α & ß (IKKα/ß) transiently reached a ∼20-fold
increase in phosphorylation (represented as p-IKK) within 10min of
TNFα stimulation (Supplementary Fig. 2A). Diminution in endothelial
cell IκB (NFĸB attenuator) levels was also observed with TNFα (10 ng/
mL) treatment in whole cell lysates. This effect, in keeping with IκB
ubiquitination and degradation, is widely reported [29–31]. Within
20min, IκB levels reached its nadir, and appeared to partially recover at
later time points (Supplementary Fig. 2B). These results illustrate that
TNFα triggers the canonical NFκB pathway in HAECs in a time-de-
pendent fashion. More importantly, administration of the novel small
molecule Nox2 inhibitors revealed that TNFα (10 ng/ml, 10min)-acti-
vated IKKα/ß was concentration-dependently attenuated by both
CPP11G and CPP11H (Fig. 4A). Characteristically, TNFα-ablated IκB
levels were partially but significantly rescued by both inhibitors at a
concentration as low as 5 μmol/l (Fig. 4B). Consistent with these ob-
servations, NFκB p65 activation/phosphorylation in whole cell lysates
was highly elevated by TNFα (10 ng/ml, 1 h) (4.3 ± 0.2 fold vs. Ctrl).
Both agents suppressed this response (Fig. 4C). Upon interrogation of
NFκB p65 nuclear translocation using fluorescence microscopy
(Fig. 4D), TNFα (10 ng/ml, 1 h) discernibly increased the levels of p65
in HAEC nuclei, which were abolished by CPP11H (10 μmol/l), and
were trending towards an inhibition by CPP11G (10 μmol/l). To further
validate these results, we compared the phospho-p65 levels in the nu-
clear extract isolated from endothelial cells. Phospho-p65 in the nuclear
fraction (p-p65 vs. histone) was substantially potentiated by TNFα
(10 ng/ml) (29.1 ± 2.2 fold vs. control). In accordance with our ob-
servation on immunofluorescent images, pretreating cells with CPP11H
but not CPP11G significantly attenuated phospho-p65 in the nuclear
extract (Supplemental Fig. 2E). These findings demonstrate that while
both agents elicit inhibitory actions on the proximal NFκB pathway,
CPP11H uniquely displays efficacy with respect to NFκB nuclear
translocation.
2.4. CPP11G and CPP11H ameliorate endothelial inflammation and
monocyte adhesion in response to TNFα
Upon activation of NFκB and AP-1 signaling cascade, inflammatory
endothelial activation response ensues with upregulated expression of
adhesion molecules [26], including vascular cell adhesion molecule-1
(VCAM-1), intracellular adhesion molecule-1 (ICAM-1) and E-selectin,
all of which facilitate the recruitment of neutrophils and monocytes,
and predispose for vascular inflammation and atherosclerosis [32]. We
first investigated the ability of the tetrahydroisoquinolines [19] to
suppress TNFα-adhesion molecule upregulation at the protein level.
Treating HAECs with TNFα for 24 h (a time point selected based on
Supplementary Figs. 2C and D illustrating that VCAM-1 and ICAM-1 are
stimulated in a time-dependent manner with maximal and robust in-
ductions appearing at 24 h respectively) promoted the levels of VCAM-1
and ICAM-1 by ∼50-fold and ∼20-fold, respectively, which were
sharply repressed by CPP11G and CPP11H in a concentration-depen-
dent fashion. Remarkably, VCAM-1 and ICAM-1 expression were vir-
tually abolished at the highest concentrations (10 μmol/l) (Figs. 5A and
B). To confirm these observations, a monocyte recruitment assay was
performed comparing calcein-labelled monocyte adherence to HAECs
in response to different treatments. As is shown in Fig. 5C, TNFα
(10 ng/ml, 24 h) stimulation markedly promoted monocyte adhesion to
HAECs as indicated by a 2.2 ± 0.2-fold increase in fluorescence in-
tensity of monocytes compared to control. Pretreating HAECs with ei-
ther inhibitor concentration-dependently diminished the TNFα-induced
response, with 10 μmol/l CPP11G or CPP11H by 30.9 ± 1.3% or
29.1 ± 2.4%, respectively. These findings point to the novel Nox2
inhibitors as efficacious agents in ameliorating endothelial activation
and chemoattraction of monocytes.
2.5. Nox2 inhibition decreases ROS production and ameliorates endothelial
dysfunction in response to TNFα in vivo
To test the clinical relevance of these agents in preventing ROS
production and preserving vascular functionality, we employed an
acute inflammatory mouse model as per cytokine challenge. Mice were
initially injected with either vehicle (30% DMSO in PBS), CPP11G
(15mg/kg) or CPP11H (15mg/kg) by i.v. bolus. Subsequently, TNFα
(20 μg/kg) was administered by i.v. bolus in mice in the TNFα plus/
minus CPP11G and CPP11H groups. To evaluate the effectiveness of
CPP11G and CPP11H in ROS (hydrogen peroxide, H2O2) production in
vivo, we employed Amplex Red to examine levels of H2O2 production in
aortic homogenates. We observed that aortas taken from mice treated
with TNFα alone generated 69.1 ± 12.5% higher H2O2 in comparison
to the control group. Importantly, H2O2 levels were significantly lower
in mice pretreated with CPP11H and trending toward a reduction by
CPP11G (Fig. 6A). These observations suggest that the inhibitors are
efficacious in limiting Nox2-derived ROS generation in vivo. Clinical
significance of these novel Nox2 inhibitors was also exemplified by
their beneficial effects on endothelial inflammation. In particular,
ICAM-1 protein levels on the aortic intima were augmented con-
siderably by TNFα stimulation (Fig. 6B). DAPI (blue) and α-actin
(green) staining show the bulk of tissue staining in the media while
merged images depict positive ICAM-1 (red) staining along the luminal
lining of the vessel. ICAM-1 expression was visibly reduced in mice
treated with both inhibitors and this decrease reached significance in
the CPP11H group (Fig. 6B; lower magnification images shown in
Supplementary Fig. 3).
To explore effects on vascular function, we evaluated mouse hind-
limb blood flow (Fig. 6C). Compared to mice in the control group,
TNFα-stimulated mice exhibited a 25.7 ± 7.3% decrease in basal fe-
moral artery blood flow (highest degree of flux shown in red). However,
when mice were pre-injected with either agent, femoral artery blood
flow was restored to or even slightly above basal levels, indicating that
the Nox2 inhibitors are able to ameliorate TNFα-mediated blood flow
disturbance in vivo.
Further, effects on endothelial dilatory function were interrogated
using ex vivo two-pin myography. Aortic rings were isolated and
mounted on two pins, and stimulated in myograph organ chambers
with TNFα (100 ng/ml) for 2 h in the presence or absence of inhibitors.
Acetylcholine (ACh: 10−8-10−5 mol/l) evoked a characteristic con-
centration-dependent vasorelaxation which was substantially impaired
in aortic rings incubated with TNFα (Fig. 6D). In contrast, pretreating
the aortic rings with either CPP11G (20 μmol/l) or CPP11H (20 μmol/l)
prevented TNFα-induced endothelial dysfunction (Fig. 6D), pointing to
the capability of both compounds to preserve endothelial cell function.
Control experiments using sodium nitroprusside (SNP: 10−9.5-
10−6mol/l) as a direct smooth muscle vasodilator displayed no change
among the treatment groups (Supplementary Fig. 4). These results de-
monstrate that neither TNFα nor Nox2 inhibitors alter smooth muscle
cell vasomotor tone.
3. Discussion
Herein, we interrogated the capacity of novel Nox2-selective small
molecule inhibitors CPP11G and CPP11H to alter endothelial ROS
production, vascular inflammatory responses and dilator function. The
major findings of the current study are the ability of these inhibitors to
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1) disrupt canonical p47phox-p22phox interaction, p47phox membrane
translocation and interaction with the membrane-bound Nox2 subunit
in the heterologous Nox2 isozyme; 2) abrogate TNFα-stimulated Nox2-
derived ROS, MAPK, AP-1 and NFκB pathway activation in human
endothelial cells; 3) limit TNFα-stimulated endothelial adhesion mole-
cules and monocyte adherence; 4) prevent in vivo TNFα-elicited ROS
production and vascular endothelial inflammatory response; 5) ame-
liorate ex vivo endothelial dysfunction; and 6) preserve hind-limb blood
flow in mice. Collectively, these findings indicate that the novel
inhibitors are highly efficient at inhibiting Nox2-mediated signaling
cascades and protecting vascular function against inflammatory insults
both in human endothelial cells and in an in vivo mouse model of sys-
temic inflammation.
The small molecule Nox2-selective inhibitors described herein were
originally identified by high-throughput screening assay of a subset of
approximately 600 small molecules from the University of Pittsburgh
Chemical Methodologies and Library Development (UPCMLD) library,
followed by structure-activity relationship (SAR) studies of newly
Fig. 4. Nox2 inhibitors attenuate TNFα-induced HAEC NFΚB pathway activation. (A) Representative Western blots (left) and cumulative data (right) showing con-
centration-dependent inhibition by CPP11G and CPP11H of TNFα (10 ng/ml, 10 min)-stimulated IKK phosphorylation. The phospho-IKK bands were quantified and
normalized to the levels of total IKKβ detected in the same samples, n = 8. (****p < 0.0001 vs. unstimulated, ####p < 0.0001 vs. TNFα). (B) Representative
Western blots (left) and cumulative data (right) showing concentration-dependent partial reversal of TNFα (10 ng/ml, 20 min)-diminished IΚB levels by CPP11G and
CPP11H. The IΚB bands were quantified and normalized to the levels of ß-actin detected in the same samples, n = 6. (****p < 0.0001 vs. unstimulated, #p < 0.05
vs. TNFα, ####p < 0.0001 vs. TNFα). (C) Representative Western blots (left) and cumulative data (right) showing concentration-dependent inhibition of TNFα
(10 ng/ml, 1 h)-stimulated NFΚB p65 phosphorylation by CPP11G and CPP11H. The phospho-bands were quantified and normalized to the total levels of p65 detected
in the same samples, n = 6. (****p < 0.0001 vs. unstimulated, #p < 0.05 vs. TNFα, ###p < 0.001 vs. TNFα, ####p < 0.0001 vs. TNFα). (D)
Immunofluorescence microscopy (60 X magnification) detection of NFΚB (red) nuclear translocation induced by TNFα (10 ng/ml, 1 h) and inhibited by CPP11G
(10 μmol/l) and CPP11H (10 μmol/l). Nuclei were labelled with DAPI (blue) to visualize cells. The fluorescence intensity was quantified from 3 images/group, n = 3
independent experiments. (*p < 0.05 vs. Ctrl, #p < 0.05 vs. TNFα).
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synthesized molecules containing a common backbone structure [19].
Among these molecules, CPP11G and CPP11H emerged as highly effi-
cacious and selective inhibitors for the Nox2 isozyme [19] exhibiting no
inhibition of Nox1, 4, or 5 isozymes or xanthine oxidase, thus demon-
strating no direct ROS scavenging properties. By comparison, the con-
temporaneous existing tools for Nox2 inhibition, including diphenylene
iodonium (DPI), apocynin, VAS2870 and ebselen congeners, presented
limitations ranging from non-selective Nox inhibition to formidable off-
target effects, prognostic of undesired consequences in vivo and a poor
Nox2-selective therapeutic [17,18]. Therefore, with high specificity and
no observed off-target effects, CPP11G and CPP11H held significant
promise as therapeutic agents for Nox2-mediated pathologies. Their
actions, however, in parenchymal cells in vitro and in vivo had not been
studied.
Aiming to gain insights into the mechanisms underlying their Nox2
suppression, in silico analyses of various Nox2 subunit interactions were
performed. Computational modeling predicts that CPP11G and CPP11H
interfere with a critical interaction of a proline-rich binding domain
within the C-terminus of p22phox which binds to a well-characterized
Src-homology 3 (SH3) “super groove” in the p47phox subunit involved in
requisite assembly and canonical Nox2 isozyme activation [20–23,33]
(Fig. 1A). Consistent with this prediction, we found that both agents: 1)
abrogated translocation of p47phox from the cytosol to plasma mem-
brane where Nox2 (aka gp91phox) and p22phox are juxtaposed and reside
(Fig. 1B); and 2) disrupted the canonical active enzyme-essential
p47phox:Nox2 interaction (Fig. 1C). These findings corroborate that by
way of impeded p47phox interaction with the membrane-bound
cytochrome (CYBB & CYBA), these agents disrupt the assembly of the
Nox2 isozyme complex, thus achieving inhibition. A similar mechanism
of action has been reported for the previously described peptidic Nox2
inhibitor, Nox2ds-tat, which blocks the interaction between Nox2 and
p47phox by binding to the latter and preventing p47phox membrane
translocation [34,35]. The most salient perceived drawback of that
agent is a limited oral bioavailability as a peptide in its current form.
Another small molecule inhibitor, celastrol, appears to disrupt binding
of a p22phox proline-rich peptide to the tandem SH3 domain of both
p47phox and NoxO1 (homolog for p47phox in the Nox1 system) [36].
However, celastrol is expected to have multiple off-target effects, as it
also inhibits cytosolic factor-independent Nox isoforms such as Noxs 4
and 5 [36]. Furthermore, another group of small molecules, namely
ebselen and congeners, appear to also interrupt the binding of the SH3
domain of p47phox to the proline-rich domain of p22phox, and prevent
p47phox and p67phox translocation to the plasma membrane in neu-
trophils [37]. However, ebselen and its analogs exhibited poor se-
lectivity for Nox2 over Nox1 with the exception of one congener, JM-
77b, which showed relatively higher selectivity, namely a lower IC50 for
Nox2 compared to Nox1 and Nox5 with no detectable inhibition of
Nox4 [37]. In addition, ebselen and its analogs have been reported to
affect numerous targets, including protein kinase C [38], endothelial
nitric oxide synthase [39,40], lipoxygenases [41], c-Jun N-terminal
kinase [40] and horseradish peroxidase [42]. Therefore, whether or not
they directly prevented p47phox and p67phox membrane translocation or
indirectly mitigated Nox activation remains undefined.
An important question that has not been addressed in the current
Fig. 5. Nox2 inhibitors attenuate TNFα-induced endothelial cell activation. (A, B) Representative Western blots (left) and cumulative data (right) showing con-
centration-dependent inhibition of TNFα (10 ng/ml, 24 h)-stimulated VCAM1 (A) and ICAM (B) expression by CPP11G and CPP11H. VCAM-1 and ICAM-1 bands
were quantified and normalized to the levels of ß-actin detected in the same samples, n = 4. (****p < 0.0001 vs. unstimulated, ##p < 0.01 vs. TNFα,
####p < 0.0001 vs. TNFα). (C) Representative data (10 X magnification) (left) of monocyte adhesion assay showing inhibition by CPP11G (10 μmol/l) and
CPP11H (10 μmol/l) on TNFα (10 ng/ml, 24 h)-induced monocyte attachment. Summary data (right) showing the concentration-dependent effects of CPP11G and
CPP11H on TNFα (10 ng/mL, 24 h)-induced monocyte adhesion. ****p < 0.0001 vs. unstimulated, #p < 0.05 vs. TNFα).
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study is whether CPP11G and CPP11H could disrupt Nox1 activity in a
hybrid system that employs p47phox as its organizing subunit [43]. That
is, the crucial isozyme-activating p47phox: p22phox interaction not only
sustains Nox2 isozyme activation, but is also operant in a hybrid Nox1
system wherein, in lieu of NoxO1, p47phox is utilized as a cytosolic or-
ganizer. The hybrid Nox1 system has been reported to be functional in
vascular smooth muscle cells [43,44] and in a variety of disease settings
[17,45,46]. With that said, one limitation of this work is that to-date
CPP11G/H mechanism of action studies have only been conducted in a
cell system that expresses the canonical Nox2 subunits (Nox2, p22phox,
p47phox, p67phox, and Rac 1/2). Thus, whether CPP11G and CPP11H
inhibit the hybrid Nox1-p47phox interaction warrants further in-
vestigation.
A process wherein Nox2-dependent ROS production has been
implicated is inflammation [47–49]. A defense response to injury that
involves a cascade of cellular signaling responses, inflammation and its
mediators initiate endothelial activation and expression of membrane
adhesion molecules, all of which are needed for monocyte recruitment
and infiltration [50]. However, when ROS production is sustained, it is
noted to give rise to chronic inflammation and endothelial dysfunction,
and underlie the pathophysiology of many cardiovascular and non-
cardiovascular disorders [49]. One of the most widely studied pro-in-
flammatory cytokines, tumor necrosis factor alpha (TNFα), has been
shown to induce endothelial activation by increasing Nox-derived ROS
production and by engaging the NFκB pathway to increase expression
of inflammatory genes such as those for cytokines and adhesion mole-
cules [47,51,52].
With respect to the current study, several lines of evidence
Fig. 6. Nox2 inhibitors ameliorate endothelial activation and improve vascular function. (A) Effects of in vivo administered CPP11G (15mg/kg) and CPP11H (15mg/
kg) on TNFα (10 μg/kg)-stimulated H2O2 in homogenates from aortas taken ex vivo as measured by Amplex Red Assay. n = 6–8 mice/group. (*p < 0.05 vs. Veh,
##p < 0.01 vs. TNFα). (B) Representative images (20 X magnification) (left) and cumulative data (right) showing the immunofluorescence microscopy detection of
ICAM-1 (red) on mouse aortic cross sections. ICAM-1 expression is enhanced by TNFα (10 μg/kg) and suppressed by CPP11H (15 mg/kg). Nuclei were labelled with
DAPI (blue) to visualize cells. Smooth muscle cells were labelled with α-actin (green). Fluorescence intensity was quantified from 4 to 5 animals/group. (**p < 0.01
vs. Veh, #p < 0.05 vs. TNFα). (C) Laser Doppler flowmetry showing the in vivo effects CPP11G (15 mg/kg) and CPP11H (15 mg/kg) on TNFα (10 μg/kg)-induced
reductions in mouse hind-limb blood flow, n = 4–5 mice/group. (*p < 0.05 vs Veh, #p < 0.05 vs. TNFα, ##p < 0.01 vs. TNFα). (D) Two-pin myography
showing the effects CPP11G (20 μmol/l, left) and CPP11H (20 μmol/l, right) on TNFα (100 ng/ml)-induced endothelial dysfunction as indicated by diminished
acetylcholine-induced vasorelaxation in mouse aortas, n = 5 mice/group. (*p < 0.05 vs. Veh, #p < 0.05 vs. TNFα).
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suggested that the Nox2 isozyme is a source of ROS and a mediator of
an inflammatory response in endothelial cells. Specifically, TNFα failed
to induce oxidant generation in lung vascular endothelial cells from
Nox2 null mice [53], a response normally characterized by NFκB acti-
vation and inflammation in wild type mice. Furthermore, TNFα-in-
duced O2•− generation in pulmonary microvascular endothelial cells
was shown to be inhibited by selective Nox2 inhibitor, Nox2ds-tat, but
not by Nox1-selective inhibitor NoxA1ds, concomitant with a sup-
pressed adhesion molecule expression and monocyte adherence [52].
Still, other lines of evidence show that TNFα also induces ROS pro-
duction from alternate sources including Nox1 [54] and Nox4 [55].
With that said, further testing of the hypothesis with an additional
Nox2-selective agent that is delivered acutely and avoids compensatory
roles of other sources spurred the current studies. Moreover, the nature
of the current agents as small molecules, their selectivity, their potential
for facile oral bioavailability, and alterability for enhanced pharmaco-
kinetic and SAR properties, justified their beta-testing in the current
study. On these premises, the characterization of CPP11G and CPP11H
on inflammatory pathways was conducted in both human endothelial
cells in culture and mouse endothelial cell and vascular tissue both in
vivo and ex vivo.
We report that CPP11G and CPP11H are highly effective in reducing
TNFα-stimulated ROS production in human aortic endothelial cells
(HAECs, Fig. 2). We employed HPr+ (a cell-impermeant O2•−-specific
probe [56]) to quantify O2•− generation as the initial product of Nox2
isozyme activity. Our data show that both compounds abrogated the
HPr+ signal in these cells, in accordance with a highly effective enzy-
matic blockade. Coumarin-7-boronic acid (CBA [57]) was used for
comprehensive detection of H2O2 (the rapidly dismuted metabolite of
O2•−) on the whole cell level and similar results were observed. Em-
ploying a third assay of direct ROS detection (Amplex Red), we were
able to show that in cell homogenates, the rise in H2O2 was abolished
by the novel Nox2 inhibitors. These results corroborate by three in-
dependent biochemical assays that ROS generation was maximally in-
hibited. Furthermore, these findings were confirmed by significant
blockade of “footprint” oxidation and nitration marker 3-nitrotyrosine
(3-NT) in whole cells in culture (Fig. 2). In aggregate, the data are
strongly supportive of the ability of CPP11G and CPP11H to ablate
Nox2 activity in these cells.
Our data also show that TNFα triggers activation of inflammation-
related MAPK-AP1 signaling and the IKK-NFκB pathway in HAECs. For
one, we observed that both compounds inhibited p38 and JNK activa-
tion albeit to varying degrees. Subsequent phosphorylation/activation
of another key player involved in these pro-inflammatory pathways, c-
Jun, that in conjunction with c-Fos, comprises the AP-1 transcription
factor complex, was effectively blocked by both CPP11G and CPP11H
(Fig. 3). In addition to the MAPK-AP1 signaling cascade, TNFα-trig-
gered IKK-NFκB pathway, characterized by IKKβ activation, IκB de-
gradation and NFκB (p65) phosphorylation, was significantly mitigated
by CPP11G and CPP11H (Fig. 4), recapitulating a primary role of Nox2-
ROS in mediating TNF-induced endothelial inflammation reported by
others [28,52]. Intriguingly, our results on the c-Jun and p65 nuclear
translocation consistently show that only CPP11H, but not CPP11G,
(Figs. 3 and 4 and Supplementary Fig. 2) was able to significantly re-
duce their levels in the nucleus. The fact that CPP11G and CPP11H are
equally effective preventing ROS generation and enzyme assembly but
differ in some downstream endpoints could be explained by the distinct
time points at which the measurements are taken, thus reflecting a
difference in binding affinity/stability between both compounds. In
fact, in Fig. 2D, 3-NT footprint assessed at 24 h supports the idea that
CPP11H effects endure more strongly at later time points than those of
CPP11G. The reason for this disparity, however, remains unclear but
could also suggest a differential penetrability of the two compounds to
compartments that connect Nox2 with c-Jun or p65.
Further studies in terms of pharmacokinetic and pharmacodynamic
properties of both compounds are required to assess the possibility of
unexpected off-target effects or effects on Nox-independent functions of
p47phox. It is also worth noting that even relatively high concentrations
of CPP11G and CPP11H (10 μmol/l) were not able to completely
abolish these TNFα-activated signaling cascades. This may be attrib-
uted to a need to test even higher concentrations of the drug that ap-
proach or exceed their previously reported IC50 values [19]. Of course,
the possibility also exists that TNFα alternatively triggers these path-
ways independently of Nox2-derived ROS. Several lines of evidence
show that TNFα also induces ROS production from other sources in
different primary cell types, such as mitochondria [58,59], Nox1 [54]
and Nox4 [55]. However, whether they are subjected to TNFα regula-
tion in human aortic endothelial cells, and whether they play a role in
endothelial activation and inflammation remains undefined. In addi-
tion, though MAPKs and NFκB are generally sensitive to the redox state
of their environment, it has also been reported that MAPKs and NFκB
can be activated in a ROS-insensitive manner [60,61] as ROS sca-
vengers fail to completely abrogate receptor-induced MAPK activation,
and that activation of NFκB signaling can be achieved by direct binding
of TNFα receptor with components of the NFκB cascade through TNF
receptor-associated factor 2 (TRAF2) [62]. It is therefore plausible that
TNFα-induced endothelial activation is mediated primarily but not
exclusively by Nox2/ROS.
Apart from our studies with respect to intracellular signaling path-
ways, translational relevance was demonstrated by our findings that
CPP11G and CPP11H in vitro effectively suppressed upregulation of
adhesion molecules in response to TNFα (Figs. 5A and B) on human
cells, leading to significantly ameliorated monocyte attachment in the
presence of CPP11G or CPP11H (Fig. 5C). Furthermore, in vivo valida-
tion in this study of the novel compounds is consistent with our in vitro
results. That is, in vivo administration of TNFα prominently enhanced
aortic H2O2 production and intimal ICAM-1 expression. Both these re-
sponses were more effectively suppressed by CPP11H than CPP11G
(Figs. 6A and B). Indeed, it has been well established that the MAPK,
AP-1 and NFκB pathways control adhesion molecule expression and
monocyte adhesion [26,47,51]. In aggregate, ROS production, adhesion
molecule expression and monocyte adhesion in vitro and ROS and ad-
hesion molecule expression in mouse aortas in vivo were ameliorated
significantly by CPP11H indicative of its effectiveness in alleviating
Nox2-mediated vascular inflammation.
Endothelial activation has been shown to potentiate endothelial
dysfunction not only by inhibiting eNOS expression [63], but also by
decreasing NO bioavailability through induction of O2•− and genera-
tion of ONOO− [64,65]. In line with this notion as well as a number of
studies by others [66–69], we also observed that incubation of mouse
aortas with TNFα led to a significantly blunted vasodilatory response to
the endothelium- and NO-dependent vasodilator acetylcholine. More
importantly, the novel small molecule inhibitors were able to largely
prevent TNFα-induced endothelial dysfunction (Fig. 6D). The protec-
tive role of Nox2 inhibition on endothelial function has been reported
by several groups. For instance, in type 2 diabetic mouse models,
Nox2ds-tat (aka gp91ds-tat)-treated mesenteric and coronary arteries
exhibited improved vasodilation to acetylcholine compared to un-
treated vessels [70]. Moreover, knocking out p47phox as well as Nox2
prevented disruption of endothelium-dependent vasodilation under
pathological conditions [9,70].
In agreement with those findings, novel Nox2 inhibitors CPP11G
and CPP11H appear to have conferred protection by abolishing TNFα-
induced ROS production and ameliorating endothelial dysfunction.
Further, disrupted endothelial function hampers the ability of arteries
and arterioles to dilate in response to endogenous vasodilatory agents,
and as a result, limits local and systemic blood flow. Indeed, we found
that treating mice with TNFα significantly decreased hind limb blood
flow, which is consistent with our results regarding endothelial dys-
function in aortas. Though these measurements were employed on
different vascular beds (femoral arteries and aortas, respectively), it
stands to reason that endothelial function in femoral arteries was also
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impaired, leading to reduced hind limb blood flow. Surprisingly,
though Nox2-selective inhibitor Nox2ds-tat was applied to cerebral
circulation to identify the involvement of Nox2 in cerebral blood flow
modulation [71,72], there are no other studies, to our knowledge, on
Nox2-mediated systemic blood flow regulation under physiological or
pathological conditions. Here, for the first time, we show that the novel
Nox2 inhibitors CPP11G and CPP11H effectively preserved normal
peripheral blood flow against inflammatory insults and protected vas-
cular function. As a decrease in blood flow, particularly in resistance
arteries, is associated with increase in blood pressure, our current result
is partially supported by one of our previous studies in which Nox2ds-
tat attenuated systolic blood pressure elevation in mice infused with
AngII [35]. Both studies indicate that targeted Nox2 inhibition pro-
motes vascular protection in various disease models, and that CPP11G
and CPP11H hold significant promise clinically for preventing and
treating Nox2-associated pathologies.
It is also noteworthy that CPP11H generally exhibits higher efficacy
compared to CPP11G. In particular, in vivo results on mouse aortas il-
lustrate that CPP11H reduced ROS production and ICAM expression
perhaps to a higher degree than CPP11G. This might be attributed to
the different structures of the side chains on the amine group: pentyl
and thiophene functional groups for CPP11G and CPP11H, respectively
[19]. These functional groups are distinct in their bulkiness, rigidity
and hydrophobicity, all of which could influence drug-protein binding
affinity. It is plausible that the thiophene functional group on CPP11H
presents a better fit for the hydrophobic pocket of the “super groove” on
the SH3 domain of p47phox for p22phox docking, thereby yielding higher
efficacy. In addition, the distinct functional groups could also affect
drug absorption, distribution, metabolism and excretion in vivo, leading
to varied efficacy. Interrogation of whether CPP11H possesses higher
binding affinity, better tissue penetration, slower metabolism or less
excretion than CPP11G will require thorough biochemical and phar-
macokinetic studies that are currently beyond the scope this work.
Collectively, these data provide exciting new evidence for the role of
Nox2 in vascular inflammation. They also illustrate effectiveness for
novel small-molecule Nox2-selective inhibitors CPP11G and CPP11H in
ameliorating TNFα-elicited endothelial inflammation and dysfunction
in human cells in vitro and in mice in vivo. More development in the way
of improving potency will likely be necessary to render more effective
and clinically relevant agents. Nevertheless, their manifold and pro-
found effects on key inflammatory pathways as well as cell and tissue
function justify their development and appear to hold significant pro-
mise for this new class of therapeutics for Nox2-mediated inflammatory
vascular diseases, such as atherosclerosis and restenosis.
4. Methods
4.1. Reagents
Superoxide dismutase (SOD) and catalase were purchased from
Sigma-Aldrich (St. Louis, MO). Protease inhibitor and phosphatase in-
hibitor cocktail tablets were purchased from Roche Diagnostics GmbH
(Mannheim, Germany). Antibodies for phospho-p38 (#4631), total p38
(#9228), phospho-SAPK/JNK (#9255), total SAPK/JNK (#9252S),
phospho-p44/42 (#8544), total p44/42 (#4695), phospho-IKKα/β
(#2697), total IKKβ (#8943), total IκB (#4814), phospho-cJun
(#3270), total cJun (#9165), phospho-NFκB p65 (#3033), total NFκB
p65 (#8242) were purchased from Cell Signaling Technology (Danvers,
MA). VCAM-1 (sc-13160), ICAM-1 (sc-19584), and β-Actin (sc-47778)
antibodies were purchased from Santa Cruz Biotechnology (Dallas, TX).
Nox2 antibody (ab129068) was purchased from Abcam (Cambridge,
MA) and p47phox antibody (07-001) was purchased from Millipore
(Burlington, MA). Rabbit (925-68070), mouse (925-68071) and goat
(925-68074) secondary antibodies were purchased from LI-COR
Biosciences (Lincoln, NE). The nuclear extract kit (40010) was pur-
chased from Active Motif (Carlsbad, CA). Coumarin 7-boronic acid
(CBA) (1357078-03-5) was purchased from Cayman Chemical (Ann
Arbor, MI). Hydropropidine (HPr+) was generously provided by Dr.
Jacek Zielonka (Medical College of Wisconsin).
4.2. 3-D modeling
Smina [73] was used to dock CPP11G and CPP11H to p40phox (from
a p40phox-p47phox complex, PDB 1W70) [74], p47phox (from a p47phox-
p22phox complex, PDB 1OV3) [23], and p67phox (from a p67phox-p47phox
complex, PDB 1K4U) [75] at the protein-protein interface. The docking
box was defined by the corresponding ligand peptide of each structure.
Water and cofactors were removed from the receptor protein, and an
exhaustiveness level of 50 was used with other parameters kept at their
defaults. Poses docked to p47phox exhibited>1 kcal/mol improved
binding affinity compared to poses docked to p40phox and p67phox.
4.3. Cell culture
COS-phox cells, kindly provided by Dr. Mary Dinauer, were cultured
in Dulbecco's Modified Eagle Medium (DMEM) with 4.5 g/l glucose, L-
glutamine and sodium pyruvate containing 10% heat-inactivated fetal
bovine serum (FBS), 100 units/ml penicillin and 100 μg/ml strepto-
mycin (complete media) (Gibco, Carlsbad, CA). Human aortic en-
dothelial cells (HAECs) from at least three different donors were ob-
tained from Lonza (CC-2535; Walkersville, MD) and cultured in EBM-2
medium containing EGM-2 bullet kit components (CC-3182, Lonza) at
5% CO2, 37 °C. Passages 3 to 6 were used for subsequent experiments.
COS-phox cells and HAECs were grown to 75-80% confluency and
subjected to serum deprivation by incubation in Opti-MEM (Gibco,
Carlsbad, CA) and endothelial cell media containing 10% of supplied
growth factors and 0.2% FBS, respectively. After 16 h, cells were
treated with CPP11G, CPP11H or vehicle (DMSO) 20min prior to the
addition of PMA (5 μmol/l) or TNFα (10 ng/ml).
4.4. Measurements of extracellular superoxide production by
hydropropidine assay
Hydropropidine (HPr+) probe preparation and methodology were
adopted and modified from a publication by Zielonka et al. [56]. HAECs
seeded in 96-well, clear-bottom, black-sided plates were serum starved
overnight. On the following day, wells were washed with PBS, and
incubated in 80 μl assay buffer consisting of Hank's Balanced Salt So-
lution supplemented with 25mmol/l HEPES, 1% BSA, 10 μmol/l DTPA,
100 μmol/l L-NAME and 1mmol/l taurine (L-NAME and taurine were
added to scavenge peroxynitrite and hypochlorous acid respectively,
which react with the probe) for 30min in an incubator (37 °C, 5% CO2).
250 U/ml superoxide dismutase (SOD) was added to select wells under
each treatment as negative controls. After incubation, probe solution
was added to each well to reach a final concentration of 100 μmol/l
HPr+ and 0.5 mg/ml salmon sperm DNA was added at a final reaction
volume of 125 μl. Plates were placed in a Biotek Synergy 4 hybrid
multimode microplate reader (preheated to 37 °C), and read kinetically
(every minute for 2 h) at excitation 400 nm and emission 574 nm. The
average rate of fluorescence generation was determined over the linear
portion of the response normalized to SOD negative controls.
4.5. Measurements of hydrogen peroxide (H2O2) production by coumarin
boronic acid (CBA) assay
CBA probe preparation was adopted and modified from methods
described by Zielonka et al. [57]. HAECs seeded in 96-well, clear-
bottom, black-sided plates were serum starved overnight, washed with
PBS, and incubated in assay buffer consisting of EC starvation media
(phenol red free) in an incubator (37 °C, 5% CO2) for 30min. Assay
buffer was supplemented with 10 μmol/l DTPA, 100 μmol/l L-NAME
and 1 μmol/l taurine. 1 KU/ml bovine liver catalase (Sigma-Aldrich, St.
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Louis, MO) was added to select wells as negative controls. After in-
cubation, probe solution was added to each well to reach a final con-
centration of 0.5 mmol/l CBA (Cayman Chemicals, Ann Arbor, MI) at a
final reaction volume of 125 μl. Plates were placed in a Biotek Synergy
4 hybrid multimode microplate reader (preheated to 37 °C), and read
kinetically (every minute for 2 h) at excitation 350 nm and emission
450 nm wavelengths. The average rate of fluorescence generation was
determined over the linear portion of the response normalized to cat-
alase negative controls.
4.6. Measurements H2O2 production by Amplex Red Assay
HAECs were collected in lysis buffer (Hank's Balanced Salt Solution
with Complete Mini protease inhibitor and PhosStop phosphatase in-
hibitor from Roche), and were lysed by five freeze/thaw cycles and
passed through a 30-gauge needle five times to disrupt cells. The cell
lysates were centrifuged at 1000 g for 5min at 4 °C to remove unbroken
cells, nuclei, and debris. Throughout all procedures, extreme care was
taken to maintain the lysate at a temperature close to 0 °C. Lysates of
human aortic endothelial cells or mouse aortic tissue were resuspended
in Amplex Red assay mixture (25mmol/l Hepes, pH 7.4, containing
120mmol/l NaCl, 3 mmol/l KCl, 1 mmol/l MgCl2, 0.1 mmol/l Amplex
red (Invitrogen, Grand Island, NY)), and 0.35 U/ml horseradish per-
oxidase (HRP) in the presence and absence of catalase (300 U/ml). The
reaction was initiated by the addition of 36 μmol/l NADPH (MP
Biomedicals, Grand Island, NY). Fluorescence measurements were
made using a Biotek Synergy 4 hybrid multimode microplate reader
with a 530/25-exitation and a 590/35-emission filter. The reaction was
monitored at 25 °C for 1 h.
4.7. Western blotting
Western blot experiments were performed as previously described
[76,77]. Tissue or cells were homogenized in ice-cold lysis buffer. Su-
pernatants were collected and lysates quantified using a Bradford assay
(Bio-Rad, Hercules, CA). Total protein (30 μg) from cell lysates was
added to Tris-glycine SDS sample buffer, boiled, resolved by SDS-PAGE
and transferred onto nitrocellulose membrane (Bio-Rad). Blots were
blocked with the Odyssey Blocking Buffer (LI-COR Biosciences, Lincoln,
NE) and probed using rabbit anti-phospho-p38 (1:500), mouse anti-p38
(1:1000), rabbit anti-phospho-SAPK/JNK (1:500), rabbit anti-SAPK/
JNK (1:1000), rabbit anti-phospho-p44/42 (1:500), rabbit anti-44/42
(1:1000), rabbit anti-phospho-IKKα/β (1:500), rabbit anti-IKKβ
(1:1000), mouse anti-IκB (1:1000), rabbit anti-phospho-cJun (1:500),
rabbit anti-cJun (1:1000), rabbit anti-phospho-NFκB p65 (1:500),
rabbit anti-NFκB p65 (1:1000) mouse anti-VCAM-1 (1:1000), mouse
anti-ICAM-1 (1:1000), mouse anti-β-Actin (1:2000), rabbit anti-Nox2
(1:1000) or rabbit anti-p47phox (1:1000). Blots were then probed with
anti-rabbit or anti-mouse secondary antibodies (1:15000 dilution, LI-
COR Biosciences). Bands were visualized on an Odyssey Imaging
System (Li-COR) and intensity quantified using ImageJ software.
4.8. Co-immunoprecipitation
COS-phox cells were serum starved in Opti-MEM for 16 h, and sti-
mulated with 5 μmol/l PMA for 1 h in the presence or absence of
CPP11G, CPP11H or vehicle (DMSO). Cells were washed with ice-cold
PBS and collected in lysis buffer (Hank's Balanced Salt Solution with
Complete Mini protease inhibitor and PhosStop phosphatase inhibitor
from Roche Diagnostics). The cells were lysed by five freeze/thaw cy-
cles and passed through a 30-gauge needle five times to disrupt cells.
The cell lysate was centrifuged at 1000 g for 5min at 4 °C to remove
unbroken cells, nuclei, and debris. Throughout all procedures, extreme
care was taken to maintain the lysate at a temperature close to 0 °C.
After pre-washing with protein A/G plus agarose (sc-2003, Santa Cruz
Biotechnology), total cell homogenates were immunoprecipitated with
anti-p47phox antibody (sc-17845, Santa Cruz Biotechnology) using
protein A/G plus agarose slurry. Immunoprecipitates were then sub-
jected to Western blotting using the anti-p47phox antibody (07-001,
Millipore) and anti-Nox2 antibody (ab129068, Abcam).
4.9. Measurement of p47phox membrane translocation
COS-phox cells were serum starved in Opti-MEM (Gibco) for 16 h,
and stimulated with 5 μmol/l PMA for 1 h in the presence or absence of
CPP11G, CPP11H or vehicle (DMSO). Cells were washed with ice-cold
PBS and collected in lysis buffer (Hank's Balanced Salt Solution (HBSS)
with Complete Mini protease inhibitor and PhosStop phosphatase in-
hibitor from Roche Diagnostics). The cells were lysed by five freeze/
thaw cycles and passed through a 30-gauge needle five times to disrupt
cells. The cell lysate was centrifuged at 1000 g for 5min at 4 °C to re-
move unbroken cells and debris. The fractions of cell nuclei, mi-
tochondria, submitochondria, and small organelles were eliminated by
sequential centrifugation at 28,000 g for 20min at 4 °C and at 100,000 g
for 60min at 4 °C. The final pellet of plasma membrane fraction was
resuspended in HBSS quantified using a Bradford assay (Bio-Rad,
Hercules, CA). 20 μg of total membrane protein were resolved by SDS-
PAGE and transferred onto nitrocellulose membrane (Bio-Rad). Blots
were probed using antibodies against p47phox (07-001, Millipore) and
Nox2 (ab129068, Abcam).
4.10. Immunofluorescent imaging
Immunofluorescence analysis was performed on HAECs grown on
gelatin-coated glass coverslips as well as 5 μm sections of paraffin-em-
bedded mouse aortas. Samples were antigen-retrieved, fixed in 2%
paraformaldehyde, permeabilized with 0.1% Triton X-100 and washed
using PBS. Sections were blocked in PBS with 2% bovine serum albumin
(BSA) for 1 h at room temperature. HAECs on coverslips were then
incubated with anti-3-nitrotyrosine (ab61392, Abcam, 1:100) for 1 h at
room temperature, or anti-total-NFκB p65 antibody (#8242, Cell
Signaling, 1:100) overnight at 4 °C followed by Cy3-conjugated sec-
ondary antibody (Life Technologies Inc., 1:1000). Coverslips were then
stained for nuclei with Hoechst dye, and cover-slipped using gelvatol
mounting media (polyvinylalcohol, glycerol, H2O, sodium azide and
Tris pH 8.5). Nonspecific rabbit or goat IgG (5 μg/ml) was used in lieu
of primary antibody as a negative control. Confocal images were cap-
tured on a Nikon A1 spectral confocal microscope (Nikon Instruments
Inc. Melville, NY). For each experiment, 3-4 images per treatment group
were captured. Three independent experiments were performed.
4.11. Monocyte adhesion assay
Confluent HAECs grown in black 96-well, clear-bottom plates were
pretreated with CPP11G or CPP11H, then stimulated with TNF-α
(10 ng/ml) for 24 h. THP-1 monocytes (ATCC, Manassas, VA) were
tagged with the compound calcein-AM (Life Technologies, Carlsbad,
CA) (10 μmol/L) for 30min at 37 °C in RPMI-1640 (Sigma-Aldrich, St.
Louis, MO) and were washed once with PBS and resuspended in RPMI-
1640 at a concentration of 5× 105 cells/ml. The tagged THP-1
(5×104 cells/well) were gently added to the HAEC monolayer and
incubated for 1 h at 37 °C. Unbound THP-1 cells were discarded by
washing with RPMI-1640 3 times followed by PBS washing once.
HAEC-attached THP-1 cells were observed with a Zeiss Axiovert 40 CFL
microscope (Carl Zeiss Microscopy, Thornwood, NY) at 10 X magnifi-
cation. In parallel, fluorescence intensity was determined using a
fluorescence microplate reader (BioTek) at 495 nm (excitation wave-
length) and 515 nm (emission wavelength). Results were shown as re-
lative monocyte adhesion levels normalized to the control group.
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4.12. Animals
All animal experiments were approved by the Institutional Animal
Care and Use Committee, University of Pittsburgh and are in ac-
cordance with National Institutes of Health guidelines. Mice purchased
from Jackson Labs (Bar Harbor, ME, USA) were subjected to i.v. bolus
injections of CPP11G or CPP11H (15mg/kg, 100 μl) or vehicle (30%
DMSO in PBS, 100 μl) into the jugular vein 15min prior to TNF-α
treatment (10 μg/kg, 100 μl). Animals were allowed to recover for 4 h,
then sacrificed and aortic vessels collected.
4.13. Laser Doppler blood flow analysis
Femoral artery blood flow was assessed 4 h after i.v. bolus injection
of TNFα (10 μg/kg) in the presence or absence of CPP11G or CPP11H
(15mg/kg). Briefly, mice were anesthetized with 2.5% isoflurane and
placed in a supine position on a heating pad. Core temperatures were
maintained at 37 °C and continuously monitored by rectal probe ther-
mometer. In order to reveal the femoral artery and adjacent arterioles
and capillaries, the inner hind limb was shaved and the skin removed to
better expose subcutaneous tissue. Real-time blood flow was measured
using laser Doppler imaging (MoorLDI-2λ; Moor Instruments, Devon,
UK).
4.14. Vessel myography
Male C57/B6 mice were anesthetized with CO2 followed by cervical
dislocation. Descending thoracic aortas were quickly isolated and cut
into 4 rings each 2mm in length. Aortic rings were placed on myograph
stirrups (Danish Myo Technology, Atlanta, GA) in 5ml physiological
saline solution (PSS) buffer (containing 130mmol/L NaCl, 4.7 mmol/l
KCl, 1.17mmol/l MgSO4, 1.18mmol/l KH2PO4, 14.9 mmol/l NaHCO3,
5.5 mmol/l D-glucose, 1.6mmol/l CaCl2, 0.026mmol/l EDTA) main-
tained at 37 °C, pH 7.4, gassed with 95% O2 and 5% CO2, and brought
to an optimal resting tension of 5000mg by increasing tone by 500mg
every 5min. Vessels were then allowed to equilibrate until baseline
tension remained constant (30-60min). Viability of the vessels was
ascertained by a series of contractile responses to KCl (25mmol/l,
50 mmol/l and 100mmol/l KCl in PSS solution) for 5min each.
Concentration-response curves to phenylephrine were carried out and a
concentration that produced 80% maximum contraction (EC80) was
chosen for establishing vascular tone prior to additional treatments. In
PE-preconstricted vessels, endothelium-dependent dilatation in re-
sponse to acetylcholine (10−9 to 10−5mol/l) and endothelium-in-
dependent dilatation in response to sodium nitroprusside (SNP) (10−9.5
to 10−6mol/l) were then tested.
4.15. Statistical analyses
Data are expressed as mean ± SEM, and for comparison of results
between two data sets, an unpaired Student's t-test was performed. One-
way ANOVA followed by Tukey's multiple comparison test was used for
comparison of results among more than two groups. Both analyses were
performed using GraphPad Prism software (version 7.1). p < 0.05 was
considered statistically significant.
4.16. Study approval
All animal experiments were approved by the Institutional Animal
Care and Use Committee, University of Pittsburgh and are in ac-
cordance with National Institutes of Health guidelines.
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